Get the Stockscreener App
1.9701
1.54%
0.0201
Medicinova Inc stock is traded at $1.9701, with a volume of 31,206.
It is up +1.54% in the last 24 hours and up +11.24% over the past month.
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
See More
Previous Close:
$1.95
Open:
$1.92
24h Volume:
31,206
Relative Volume:
0.41
Market Cap:
$89.26M
Revenue:
-
Net Income/Loss:
$-9.51M
P/E Ratio:
-7.8804
EPS:
-0.25
Net Cash Flow:
$-10.96M
1W Performance:
+8.49%
1M Performance:
+11.24%
6M Performance:
+42.45%
1Y Performance:
+6.45%
1-Day Range:
$1.92
$1.9883
1-Week Range:
$1.70
$1.9883
52-Week Range:
$1.12
$2.55
Medicinova Inc Stock (MNOV) Company Profile
Name
Medicinova Inc
Sector
Industry
Phone
858-373-1500
Address
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Compare MNOV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| MNOV | 1.97 | 89.26M | 0 | -9.51M | -10.96M | -0.25 |
| VRTX | 446.25 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.93 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.43 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.89 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.94 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-21 | Initiated | Maxim Group | Buy |
| Mar-25-19 | Resumed | B. Riley FBR | Buy |
| Mar-28-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-18-17 | Initiated | Credit Suisse | Outperform |
| Jan-04-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-24-12 | Downgrade | MLV & Co | Buy → Hold |
| Oct-18-11 | Reiterated | MLV Capital | Buy |
| Jun-22-11 | Initiated | Global Hunter Securities | Buy |
| May-12-10 | Initiated | Wedbush | Outperform |
| Nov-12-08 | Reiterated | Ladenburg Thalmann | Buy |
| May-15-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jul-09-07 | Initiated | Punk, Ziegel & Co | Buy |
View All
Medicinova Inc Stock (MNOV) Latest News
MediciNova reports progress in ALS and Long COVID trials - Investing.com
MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders - GlobeNewswire
MediciNova Partners with NIH for ALS Trial, Reports $42.3M Cash Position | MNOV Stock News - StockTitan
StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV) - Defense World
MediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.com - MarketBeat
MediciNova Receives Notice of Allowance from United States - GlobeNewswire
MediciNova Secures Key Patent for Diabetes Treatment MN-001 Through 2042 | MNOV Stock News - StockTitan
MediciNova stock hits 52-week high at $2.17 amid growth - Investing.com India
MediciNova: Q3 Earnings Snapshot - New Haven Register
3 US Penny Stocks With Market Caps Over $40M To Consider - Simply Wall St
MediciNova stock hits 52-week high at $2.17 amid growth By Investing.com - Investing.com UK
MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis - The Manila Times
MediciNova Secures Major Settlement from Sanofi-Novartis Litigation, Boosts Clinical Pipeline | MNOV Stock News - StockTitan
Idiopathic Pulmonary Fibrosis Management Market Share and Size Report 2024-2031 - InsightAce Analytic
MediciNova (NASDAQ:MNOV shareholders incur further losses as stock declines 11% this week, taking five-year losses to 80% - Simply Wall St
MediciNova (NASDAQ:MNOV) Share Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com - MarketBeat
TSX Buyback Index (TXBB) QuotePress Release - The Globe and Mail
Idiopathic Pulmonary Fibrosis Market Is Booming Worldwide - openPR
MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com - Defense World
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV) - MarketBeat
MediciNova (NASDAQ:MNOV) Shares Cross Above Two Hundred Day Moving Average – Should You Sell? - Defense World
MediciNova (NASDAQ:MNOV) Stock Price Crosses Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Clean Harbors (CLH-N) QuotePress Release - The Globe and Mail
MediciNova Announces Update of Phase 2/3 Clinical Trial of - GlobeNewswire
MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) - StockTitan
MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com - MarketBeat
MediciNova (NASDAQ:MNOV) Research Coverage Started at StockNews.com - Defense World
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
MediciNova, Inc. (NASDAQ:MNOV) Shares Sold by Dimensional Fund Advisors LP - Defense World
Type 1 Diabetes Market Report 2034: Epidemiology Data, Pipeline - openPR
MediciNova (NASDAQ:MNOV) shareholders have endured a 73% loss from investing in the stock five years ago - Yahoo Finance
MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
MNOV: MN-166 to be Evaluated in NIH-Sponsored Expanded Access Trial in ALS - Smartkarma
MNOVMedicinova, Inc. Latest Stock News & Market Updates - StockTitan
Short Interest in MediciNova, Inc. (NASDAQ:MNOV) Rises By 19.3% - MarketBeat
MediciNova to Support NIH-Funded Expanded Access Clinical - GlobeNewswire
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) - StockTitan
MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average of $1.42 - MarketBeat
Amyotrophic Lateral Sclerosis Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024 - The Globe and Mail
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Stockhouse Publishing
Insigneo Advisory Services LLC Has $6.10 Million Stock Position in Mastercard Incorporated (NYSE:MA) - Defense World
Intech Investment Management LLC Takes Position in MSA Safety Incorporated (NYSE:MSA) - MarketBeat
Minerals Technologies (NYSE:MTX) Upgraded at StockNews.com - MarketBeat
Monroe Capital (NASDAQ:MRCC) Stock Crosses Above 200 Day Moving Average of $7.49 - MarketBeat
MARXU stock soars to all-time high of $12.15 amid market optimism - Investing.com Australia
Marcus (NYSE:MCS) Upgraded by StockNews.com to Hold - Defense World
Mistras Group senior EVP sells over $349k in company stock - Investing.com
Contact Levi & Korsinsky by September 24, 2024 Deadline to Join Class Action Against MacroGenics, Inc.(MGNX) - Stockhouse Publishing
Summit Trail Advisors LLC Buys 403 Shares of Moderna, Inc. (NASDAQ:MRNA) - Defense World
MacroGenics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationMGNX - Longview News-Journal
Medicinova Inc Stock (MNOV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):